FUSION PROTEIN INCLUDING GLUCAGON-LIKE PEPTIDE-1 AND INTERLEUKIN-1 RECEPTOR ANTAGONIST AND USE THEREOF
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Nov 9, 2023
app pub date -
Jul 9, 2021
filing date -
Jul 10, 2020
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
The present invention relates to a fusion protein dimer comprising glucagon-like peptide-1 (GLP-1) and an interleukin-1 receptor antagonist (IL-1Ra), and a pharmaceutical composition for treating a metabolic disease using the same. It was confirmed that the fusion protein dimer significantly acts as a GLP-1 hormone and efficiently binds to an IL-1 receptor, and thus has an excellent inhibitory effect on the signaling of IL-1β caused by inflammasomes. Therefore, the fusion protein dimer according to the present invention has the combined efficacy of GLP-1 and an IL-1 receptor antagonist and can be effectively used for treatment and prevention of metabolic diseases such as diabetes, obesity, and hyperlipidemia, and thus has a high possibility of being industrially used.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully